Analysis on Adverse Reactions Related to Camrelizumab for Injection
Objective:To investigate the adverse reactions related to camrelizumab for injection treatment in patients with malignant tumors,and to provide reference for clinical rational drug use.Methods:A retrospective study was conducted in 103 patients with malignant tumors who were treated in the hospital between January 2020 and December 2021.All patients received camrelizumab for injection during the treatment period,and the occurrence of camrelizumab for injection related adverse reactions was recorded.Results:A total of 24 different adverse reactions reported in the instructions for camrelizumab for injection occurred in 103 patients with malignant tumors,with a total of 116 times.The incidence of reactive capillary hyperplasia was the highest,accounting for 52.59%,followed by hypothyroidism,accounting for 15.52%.No fatal adverse reactions were observed.Significant differences in the incidence of adverse reactions in patients with malignant tumors were observed based on different data characteristics.The incidence of adverse reactions is higher in women and patients over 55 years old compared to men and patients aged≤55 years old.The incidence of adverse reactions in patients treated with a combination of two or more drugs of camrelizumab for injection is higher than that in those treated with a combination of one drug of camrelizumab for injection or camrelizumab for injection alone.Furthermore,the incidence of adverse reactions in patients treated with the combination of camrelizumab for injection and one drug is higher than that in patients treated with camrelizumab for injection alone.Conclusion:Numerous adverse reactions were observed in patients with malignant tumors treated with camrelizumab for injection,and the incidence is high.Sufficient attention should be paid in the clinic to enhance the monitoring of rational drug use and ensure the safety of patients.
malignant tumorcamrelizumab for injectionreactive capillary hyperplasiahypothyroidismfever
万方数据
维普
